Clinical TrialAug 6, 2026, 12:04 PM
Ascendis Pharma Achondroplasia Programs Show Strong Clinical Results
AI Summary
Ascendis Pharma provided positive updates on its achondroplasia programs, including durable growth and improved body proportionality from the combination therapy (TransCon CNP + TransCon hGH) in the COACH trial, with 100% patient retention at Week 78. The TransCon CNP monotherapy also demonstrated durable height improvements and benefits beyond height in the ApproaCH trial over 104 weeks, with a favorable safety profile. The company also reported progress on the US launch of YUVIWEL (navepegritide), with over 170 patient enrollments and 65% reimbursement approval, and anticipates an EU regulatory decision for TransCon CNP monotherapy in Q4 2026.
Key Highlights
- Combination therapy showed mean AGV of 7.73 cm/year for treatment-naïve cohort at Week 78.
- Combination therapy showed mean AGV of 7.67 cm/year for CNP-experienced cohort at Week 78.
- TransCon CNP monotherapy demonstrated durable height improvements over 104 weeks.
- TransCon CNP monotherapy had 0.35 injection-site reactions per person-year.
- Completed target enrollment for pivotal reACHin Trial for infants 0 to <2 years.
- EU regulatory decision for TransCon CNP monotherapy anticipated in Q4 2026.
- YUVIWEL US launch has over 170 patient enrollments with 65%+ reimbursement approval.
- 100% of 21 children completed 78 weeks of combination therapy in COACH trial.
Price Impact
More from ASND